NO20064848L - Imidazolforbindelser - Google Patents

Imidazolforbindelser

Info

Publication number
NO20064848L
NO20064848L NO20064848A NO20064848A NO20064848L NO 20064848 L NO20064848 L NO 20064848L NO 20064848 A NO20064848 A NO 20064848A NO 20064848 A NO20064848 A NO 20064848A NO 20064848 L NO20064848 L NO 20064848L
Authority
NO
Norway
Prior art keywords
imidazole
inflammation
modulating
compositions
receptor
Prior art date
Application number
NO20064848A
Other languages
English (en)
Norwegian (no)
Inventor
James P Edwards
Daniel J Buzard
David E Kindrachuk
Jennifer D Venable
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20064848L publication Critical patent/NO20064848L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B55/00—Racemisation; Complete or partial inversion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20064848A 2004-03-25 2006-10-25 Imidazolforbindelser NO20064848L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55635604P 2004-03-25 2004-03-25
PCT/US2005/009715 WO2005092066A2 (en) 2004-03-25 2005-03-24 Imidazole compounds

Publications (1)

Publication Number Publication Date
NO20064848L true NO20064848L (no) 2006-10-25

Family

ID=35056771

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064848A NO20064848L (no) 2004-03-25 2006-10-25 Imidazolforbindelser

Country Status (19)

Country Link
US (9) US7253200B2 (ko)
EP (1) EP1737297B1 (ko)
JP (1) JP5162236B2 (ko)
KR (1) KR101217103B1 (ko)
CN (1) CN101022728B (ko)
AU (1) AU2005226729B2 (ko)
BR (1) BRPI0509164A (ko)
CA (1) CA2560896C (ko)
CR (1) CR8704A (ko)
EA (1) EA011242B1 (ko)
EC (1) ECSP066882A (ko)
HK (1) HK1102020A1 (ko)
IL (2) IL178287A (ko)
MX (1) MXPA06011021A (ko)
NO (1) NO20064848L (ko)
NZ (1) NZ550087A (ko)
UA (1) UA89226C2 (ko)
WO (1) WO2005092066A2 (ko)
ZA (1) ZA200608836B (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2560896C (en) * 2004-03-25 2013-06-18 Janssen Pharmaceutica, N.V. Imidazole compounds
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
EP2004188B1 (en) * 2006-03-31 2010-09-01 Janssen Pharmaceutica NV Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor
RS51423B (en) 2006-03-31 2011-02-28 Janssen Pharmaceutica N.V. BENZOIMIDAZOL-2-IL PYRIMIDINI I KAO PYRAZID MODULATORS HISTAMINSKOG H4 RECEPTOR
US20090069343A1 (en) * 2006-04-10 2009-03-12 Dunford Paul J Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus
CL2007002007A1 (es) * 2006-07-11 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de benzofuro y benzotienopirimidinas, moduladores del receptor de histamina h4; procedimiento de preparacion; y su uso para tratar trastornos inflamatorios, alergicos, dermatologicos, enfermedades autoinmune, linfaticas y de inmu
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
TW200904437A (en) 2007-02-14 2009-02-01 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
JP5439377B2 (ja) * 2007-09-14 2014-03-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ４受容体のチエノ−及びフロ−ピリミジン調節物質
WO2009079001A1 (en) * 2007-12-18 2009-06-25 Janssen Pharmaceutica N.V. Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine h4 receptor
CA2727627C (en) 2008-06-12 2018-02-13 Janssen Pharmaceutica Nv Use of histamine h4 antagonist for the treatment of post-operative adhesions
BRPI0913989A2 (pt) * 2008-06-30 2015-10-20 Janssen Pharmaceutica Nv processo para preparação de derivados de benzoimidazol-2-il pirirmidina
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
JP5710490B2 (ja) * 2008-12-01 2015-04-30 ターガセプト，インコーポレイテッド （ｒ）−５−（（ｅ）−２−（ピロリジン−３−イルビニル）ピリミジンの合成および新規の塩形態
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
DK3199172T3 (en) * 2009-08-20 2018-10-08 Yeda Res & Dev DOSAGE regimen for multiple sclerosis
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
WO2011095450A1 (en) 2010-02-02 2011-08-11 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
PT2858647T (pt) 2012-06-08 2018-10-03 Sensorion Inibidores do recetor h4 para tratamento de tinido
MX2015011688A (es) 2013-03-06 2015-12-07 Janssen Pharmaceutica Nv Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina.
US10414766B2 (en) * 2015-12-15 2019-09-17 Alembic Pharmaceuticals Limited Polymorph of Riociguat and its process for the preparation
WO2018178973A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4187213A (en) * 1978-01-09 1980-02-05 Eastman Kodak Company Multiheterocyclic ultraviolet stabilizers and their use in organic compositions
FR2665161B1 (fr) * 1990-07-26 1992-11-27 Esteve Labor Dr Nouveaux derives de benzimidazole, leur preparation et leur application en tant que medicaments.
US6610695B1 (en) * 1997-06-19 2003-08-26 Smithkline Beecham Corporation Aryloxy substituted pyrimidine imidazole compounds
CA2349227C (en) * 1998-11-03 2008-02-05 Basf Aktiengesellschaft Substituted 2-phenylbenzimidazoles, the production thereof and their use
EP1311482B1 (en) * 2000-08-08 2007-02-21 Ortho-McNeil Pharmaceutical, Inc. Non-imidazole aryloxypiperidines as h3 receptor ligands
WO2004014900A1 (en) * 2002-08-09 2004-02-19 Eli Lilly And Company Benzimidazoles and benzothiazoles as inhibitors of map kinase
SE0202462D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel use
EP1613310A1 (en) * 2003-04-10 2006-01-11 Avanir Pharmaceuticals Imidazole derivatives for treatment of allergic and hyperproliferative disorders
US7432378B2 (en) * 2003-09-30 2008-10-07 Janssen Pharmaceutica, N.V. Benzoimidazole compounds
CA2560896C (en) * 2004-03-25 2013-06-18 Janssen Pharmaceutica, N.V. Imidazole compounds

Also Published As

Publication number Publication date
IL178287A (en) 2012-12-31
EP1737297A4 (en) 2009-07-15
AU2005226729A1 (en) 2005-10-06
US20070265250A1 (en) 2007-11-15
KR20070021186A (ko) 2007-02-22
EA011242B1 (ru) 2009-02-27
US7951808B2 (en) 2011-05-31
WO2005092066A3 (en) 2006-01-12
MXPA06011021A (es) 2007-04-13
US20100261898A1 (en) 2010-10-14
US20100261899A1 (en) 2010-10-14
BRPI0509164A (pt) 2007-09-11
KR101217103B1 (ko) 2012-12-31
CR8704A (es) 2008-11-24
US20050261309A1 (en) 2005-11-24
CN101022728B (zh) 2012-08-08
US20070173513A1 (en) 2007-07-26
EP1737297A2 (en) 2007-01-03
AU2005226729B2 (en) 2010-01-28
US7956057B2 (en) 2011-06-07
ZA200608836B (en) 2008-05-28
ECSP066882A (es) 2006-11-24
CN101022728A (zh) 2007-08-22
EP1737297B1 (en) 2012-12-19
US8017600B2 (en) 2011-09-13
WO2005092066A2 (en) 2005-10-06
US20070173512A1 (en) 2007-07-26
JP5162236B2 (ja) 2013-03-13
US7253200B2 (en) 2007-08-07
US7956071B2 (en) 2011-06-07
CA2560896A1 (en) 2005-10-06
EA200601766A1 (ru) 2007-04-27
US20070173509A1 (en) 2007-07-26
HK1102020A1 (en) 2007-11-02
US20070173510A1 (en) 2007-07-26
IL178287A0 (en) 2006-12-31
US20070149541A1 (en) 2007-06-28
NZ550087A (en) 2009-06-26
IL205159A0 (en) 2010-11-30
US7928131B2 (en) 2011-04-19
US8039498B2 (en) 2011-10-18
WO2005092066A8 (en) 2007-03-29
JP2007530570A (ja) 2007-11-01
US7956066B2 (en) 2011-06-07
UA89226C2 (en) 2010-01-11
US8017639B2 (en) 2011-09-13
CA2560896C (en) 2013-06-18

Similar Documents

Publication Publication Date Title
NO20064848L (no) Imidazolforbindelser
NO20061950L (no) Benzoimidazolforbindelser
EA201000563A1 (ru) Триазолпиридиновые ингибиторы 11-бета- гидроксистероид - дегидрогеназы типа i
NO20091326L (no) Indazolderivater som modulatorer av interleukin-1-reseptor-assosiert kinase
ATE484508T1 (de) Furylverbindungen
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
NO20044995L (no) Heterosykliske forbindelser
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
NO20082191L (no) Forbindelser
EA200900571A1 (ru) Композиции chk1 ингибиторов
NO20070910L (no) Pyrrolderivater som farmasoytiske middel
DK1735296T3 (da) Materialer og fremgangsmåder til behandling af koagulationslidelser
NO20083694L (no) Bruk av rylener som markorer for vaesker
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
WO2007024717A3 (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
NO20075275L (no) Nye forbindelser
NO20052028L (no) Pyridinderivater som CB2 reseptor modulatorer
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
NO20076515L (no) Hydantoinforbindelser
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
NO20092073L (no) Modulatorer av C3A-reseptor, og fremgangsmater for anvendelse derav
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
ATE509957T1 (de) An die a2-domäne bindende, humane inhibitorische anti-faktor-viii-antikörper

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application